156 related articles for article (PubMed ID: 21078951)
1. Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects.
Hanna GJ; Lalezari J; Hellinger JA; Wohl DA; Nettles R; Persson A; Krystal M; Lin P; Colonno R; Grasela DM
Antimicrob Agents Chemother; 2011 Feb; 55(2):722-8. PubMed ID: 21078951
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.
Nettles RE; Schürmann D; Zhu L; Stonier M; Huang SP; Chang I; Chien C; Krystal M; Wind-Rotolo M; Ray N; Hanna GJ; Bertz R; Grasela D
J Infect Dis; 2012 Oct; 206(7):1002-11. PubMed ID: 22896665
[TBL] [Abstract][Full Text] [Related]
3. Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects.
Cotte L; Dellamonica P; Raffi F; Yazdanpanah Y; Molina JM; Boué F; Urata Y; Chan HP; Zhu L; Chang I; Bertz R; Hanna GJ; Grasela DM; Hwang C
J Acquir Immune Defic Syndr; 2013 Jul; 63(3):346-54. PubMed ID: 23771104
[TBL] [Abstract][Full Text] [Related]
4. In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.
Zhou N; Nowicka-Sans B; Zhang S; Fan L; Fang J; Fang H; Gong YF; Eggers B; Langley DR; Wang T; Kadow J; Grasela D; Hanna GJ; Alexander L; Colonno R; Krystal M; Lin PF
Antimicrob Agents Chemother; 2011 Feb; 55(2):729-37. PubMed ID: 21078948
[TBL] [Abstract][Full Text] [Related]
5. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068.
Ray N; Hwang C; Healy MD; Whitcomb J; Lataillade M; Wind-Rotolo M; Krystal M; Hanna GJ
J Acquir Immune Defic Syndr; 2013 Sep; 64(1):7-15. PubMed ID: 23614999
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults.
Schürmann D; Fätkenheuer G; Reynes J; Michelet C; Raffi F; van Lier J; Caceres M; Keung A; Sansone-Parsons A; Dunkle LM; Hoffmann C
AIDS; 2007 Jun; 21(10):1293-9. PubMed ID: 17545705
[TBL] [Abstract][Full Text] [Related]
7. Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects.
Moyle G; Boffito M; Stoehr A; Rieger A; Shen Z; Manhard K; Sheedy B; Hingorani V; Raney A; Nguyen M; Nguyen T; Ong V; Yeh LT; Quart B
Antimicrob Agents Chemother; 2010 Aug; 54(8):3170-8. PubMed ID: 20498326
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
Lalezari JP; Latiff GH; Brinson C; Echevarría J; Treviño-Pérez S; Bogner JR; Thompson M; Fourie J; Sussmann Pena OA; Mendo Urbina FC; Martins M; Diaconescu IG; Stock DA; Joshi SR; Hanna GJ; Lataillade M;
Lancet HIV; 2015 Oct; 2(10):e427-37. PubMed ID: 26423650
[TBL] [Abstract][Full Text] [Related]
9. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
Min S; Sloan L; DeJesus E; Hawkins T; McCurdy L; Song I; Stroder R; Chen S; Underwood M; Fujiwara T; Piscitelli S; Lalezari J
AIDS; 2011 Sep; 25(14):1737-45. PubMed ID: 21716073
[TBL] [Abstract][Full Text] [Related]
10. Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529.
Landry I; Zhu L; Abu Tarif M; Hruska M; Sadler BM; Pitsiu M; Joshi S; Hanna GJ; Lataillade M; Boulton DW; Bertz RJ
Antimicrob Agents Chemother; 2016 May; 60(5):2782-9. PubMed ID: 26902761
[TBL] [Abstract][Full Text] [Related]
11. A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients.
Pett SL; McCarthy MC; Cooper DA; MacRae K; Tendolkar A; Norris R; Strizki JM; Williams KM; Emery S
Antivir Ther; 2009; 14(1):111-5. PubMed ID: 19320244
[TBL] [Abstract][Full Text] [Related]
12. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults.
Lalezari J; Thompson M; Kumar P; Piliero P; Davey R; Patterson K; Shachoy-Clark A; Adkison K; Demarest J; Lou Y; Berrey M; Piscitelli S
AIDS; 2005 Sep; 19(14):1443-8. PubMed ID: 16135896
[TBL] [Abstract][Full Text] [Related]
13. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team.
Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Ait-Khaled M; Purdon S
AIDS; 2000 May; 14(7):781-9. PubMed ID: 10839585
[TBL] [Abstract][Full Text] [Related]
14. VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics.
Lori F; De Forni D; Katabira E; Baev D; Maserati R; Calarota SA; Cahn P; Testori M; Rakhmanova A; Stevens MR
PLoS One; 2012; 7(10):e47485. PubMed ID: 23094055
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial.
Asmuth DM; Murphy RL; Rosenkranz SL; Lertora JJ; Kottilil S; Cramer Y; Chan ES; Schooley RT; Rinaldo CR; Thielman N; Li XD; Wahl SM; Shore J; Janik J; Lempicki RA; Simpson Y; Pollard RB;
J Infect Dis; 2010 Jun; 201(11):1686-96. PubMed ID: 20420510
[TBL] [Abstract][Full Text] [Related]
16. Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.
Goebel F; Yakovlev A; Pozniak AL; Vinogradova E; Boogaerts G; Hoetelmans R; de Béthune MP; Peeters M; Woodfall B
AIDS; 2006 Aug; 20(13):1721-6. PubMed ID: 16931936
[TBL] [Abstract][Full Text] [Related]
17. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects.
Lalezari J; Gathe J; Brinson C; Thompson M; Cohen C; Dejesus E; Galindez J; Ernst JA; Martin DE; Palleja SM
J Acquir Immune Defic Syndr; 2011 Jun; 57(2):118-25. PubMed ID: 21317794
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
Landovitz RJ; Angel JB; Hoffmann C; Horst H; Opravil M; Long J; Greaves W; Fätkenheuer G
J Infect Dis; 2008 Oct; 198(8):1113-22. PubMed ID: 18783318
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor.
Spreen W; Min S; Ford SL; Chen S; Lou Y; Bomar M; St Clair M; Piscitelli S; Fujiwara T
HIV Clin Trials; 2013; 14(5):192-203. PubMed ID: 24144896
[TBL] [Abstract][Full Text] [Related]
20. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.
Zhou N; Nowicka-Sans B; McAuliffe B; Ray N; Eggers B; Fang H; Fan L; Healy M; Langley DR; Hwang C; Lataillade M; Hanna GJ; Krystal M
J Antimicrob Chemother; 2014 Mar; 69(3):573-81. PubMed ID: 24128669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
